UNITED ~~STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549~~STATES

~~Form~~SECURITIES ~~6-K~~AND EXCHANGE COMMISSION

~~REPORT~~Washington, OFD.C. ~~FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934~~20549

~~For the month of April 2016~~___________________________

FORM 6-K

__________________________

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO

RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the Month of May 2016

Commission File Number: 333-196065

~~Parnell Pharmaceuticals Holdings Ltd(Translation of registrant's name into English)~~__________________________

~~Unit~~PARNELL 4,PHARMACEUTICALS ~~Century~~HOLDINGS ~~Estate476 Gardeners RoadAlexandria 2015 NSWAustralia(Address of principal executive office)~~LTD

~~Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.Form 20-F [ X ] Form 40-F [ ]~~__________________________

~~Indicate~~Unit by4, ~~check~~Century ~~mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):~~ Estate

~~Indicate~~476 byGardeners ~~check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):~~ Road

OnAlexandria ~~April~~2015 ~~22, 2016, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. (c) Exhibit 99.1. Press release dated April 22, 2016~~NSW

Australia

(Address of principal executive offices)

__________________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ý Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

TABLE OF CONTENTS

PARNELL PHARMACEUTICALS HOLDINGS LTD

Form 6-K

Submission of Matters to a Vote of Security Holders

On May 5, 2016, the Company held its Annual General Meeting of Stockholders. Each proposal subject to a vote at the Annual General Meeting was described in detail in the Company’s Notice of Annual General Meeting filed with the Securities Exchange Commission (SEC) on April 7, 2016. With respect to each of the proposals, the Company’s stockholders voted as indicated below.

Ratification of Appointment of Company Auditor: Stockholders ratified the Audit Committee’s appointment of PricewaterhouseCoopers as the Company’s independent registered public accounting firm for fiscal year 2016.

For	Against	Abstentions
9,843,034	5,050	6,000
99.89%	0.05%	0.06%

Election of Mr. Peter Croden as a Director of the Company: Stockholders elected Mr. Croden as follows:

For	Against	Abstentions
9,787,587	11,081	6,300
99.82%	0.11%	0.07%

Election of Ms. Ellen Richstone as a Director of the Company: Stockholders elected Ms. Richstone as follows:

For	Against	Abstentions
9,790,197	8,471	6,300
99.85%	0.09%	0.06%

Election of Dr. David Rosen as a Director of the Company: Stockholders elected Dr. Rosen as follows:

For	Against	Abstentions
9,790,662	8,006	6,300
99.85%	0.08%	0.07%

Re-election of Dr. Alan Bell as a Director of the Company: Stockholders re-elected Dr. Bell as follows:

For	Against	Abstentions
8,960,836	834,832	9,300
91.39%	8.51%	0.10%

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Parnell Pharmaceuticals Holdings Ltd
		(Registrant)
Date: April 22, 2016		/s/ Robert Joseph
		Robert Joseph
		President and CEO

		Parnell Pharmaceuticals Holdings Ltd


		By:	/s/ Robert Joseph
		Name:	Robert Joseph
		Title:	President and CEO

Date: May 16, 2016

Filing Compare · Parnell Pharmaceuticals Holdings Ltd